Showing 12 posts of 12 posts found.


Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets

July 11, 2023
Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …

Eyenovia announces FDA approval of first ophthalmic spray for mydriasis

May 10, 2023
Research and Development Eyenovia, FDA, Opthalmology, mydriasis, ophthalmology

Ophthalmic technology company Eyenovia has announced that the US Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine …

Astellas to acquire Ocata Therapeutics in $379m buyout

November 11, 2015
Research and Development, Sales and Marketing Astellas, Ocata, Stem cells, cell therapy, ophthalmology

Astellas Pharma has agreed to buy Ocata, a firm specialising in cloning and embryonic stem cell therapies, for $379 million. …


EM Imaging appoints new chairman

September 10, 2015
Manufacturing and Production, Research and Development EM Imaging, Optometry, ophthalmology

The board of Edinburgh Molecular Imaging Ltd (EM Imaging) is pleased to announce the appointment of John Jeans as non-executive …

Watermeadow shortlisted for medical education award

July 1, 2013
Medical Communications Communique, Excellence in Ophthalmology, UK, Watermeadow Medical, award-winning agency, finalist, medical education, ophthalmology, programme

Watermeadow Medical is delighted that one of its educational programmes has been shortlisted for the ‘Excellence in Professional Education Programmes’ …

Bayer drug enters phase III for diabetic macular oedema

April 11, 2011
Sales and Marketing Bayer, Lucentis, ophthalmology

Bayer and partner Regeneron have begun late stage trials for their VEGF Trap Eye candidate for diabetic macular oedema. The …

Sanofi-Aventis headquarters

Sanofi signs ophthalmology research collaboration

March 25, 2011
Research and Development Fovea, Sanofi-Aventis, Vision Institute, ophthalmology

Sanofi-Aventis has penned a collaboration with one of the main eye disease research centres in Europe. The three-year agreement between …

Novartis becomes global eye health leader as Alcon deal finalised

December 15, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Alcon, Lucentis, Novartis, eye care, eye health, ophthalmology

Novartis’ 11-month standoff with Alcon shareholders has ended, allowing it to acquire all the remaining shares in the ophthalmology firm. …

Alcon acquisition makes Novartis eyecare leader

August 26, 2010
Sales and Marketing Novartis, ophthalmology

Novartis has finalised its takeover of Alcon that will make it the world’s number one company in ophthalmology. Alcon is …

Merck launches Saflutan in first European markets

September 4, 2009
Research and Development, Sales and Marketing Merck, ophthalmology

Merck's glaucoma drug Saflutan has been launched in the UK and Spain. The manufacturer says more launches are planned in …

Pfizer taps UCL for stem cell expertise

April 28, 2009
Research and Development Pfizer, UCL, ophthalmology, regenerative medicine

 Pfizer will work with researchers from University College London in the UK to try to develop stem cell-based therapies for …

Novartis and charity team up on AMD campaign

February 18, 2009
Medical Communications, Sales and Marketing AMD, ophthalmology

Novartis has teamed up with blindness charity the RNIB on a new campaign to promote awareness of age-related macular degeneration …

Latest content